Company Summary:
  • Pi-Cardia developed the Leaflex™ Catheter System - a novel non-implant based technology for treating patients with aortic valve stenosis
  • The Leaflex™ is a low-profile trans-femoral catheter which delivers mechanical energy in order to create substantial fractures in valve calcification
Transaction Overview:
  • $10 Million Series C round completed, led by an undisclosed major strategic
Significance of the Transaction:
  • Expand the treatment options in the rapidly growing multi-billion dollar market currently dominated by surgical or trans-catheter aortic valve replacement
Healthios Role:
  • Healthios served as exclusive financial adviser to Pi-Cardia
  • This transaction highlights Healthios commitment to capital formation in emerging growth companies and our success in completing complex transaction to maximize shareholder interests